Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation

Abstract

Combined experimental and computational studies of lipid membranes and liposomes, with the aim to attain mechanistic understanding, result in a synergy that makes possible the rational design of liposomal drug delivery system (LDS) based therapies. The LDS is the leading form of nanoscale drug delivery platform, an avenue in drug research, known as "nanomedicine", that holds the promise to transcend the current paradigm of drug development that has led to diminishing returns. Unfortunately this field of research has, so far, been far more successful in generating publications than new drug therapies. This partly results from the trial and error based methodologies used. We discuss experimental techniques capable of obtaining mechanistic insight into LDS structure and behavior. Insight obtained purely experimentally is, however, limited; computational modeling using molecular dynamics simulation can provide insight not otherwise available. We review computational research, that makes use of the multiscale modeling paradigm, simulating the phospholipid membrane with all atom resolution and the entire liposome with coarse grained models. We discuss in greater detail the computational modeling of liposome PEGylation. Overall, we wish to convey the power that lies in the combined use of experimental and computational methodologies; we hope to provide a roadmap for the rational design of LDS based therapies. Computational modeling is able to provide mechanistic insight that explains the context of experimental results and can also take the lead and inspire new directions for experimental research into LDS development. This article is part of a Special Issue entitled: Biosimulations edited by Ilpo Vattulainen and Tomasz Róg.

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

“…The ratio between the main lipid (DPPC) and the PEGylated lipid (PEG-DSPE) was kept constant throughout the experimental plan (5% PEGylated lipid of the total phospholipid concentration) and was not considered a formulation factor. The reason behind PEGylation is to improve the stability and biological performance of liposomes in vivo by extending their circulation time in the bloodstream 38. Since the proposed liposomal system was not yet assessed in vivo, it was not considered necessary to study the influence of the degree of PEGylation on the characteristics of the liposomes.…”

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

“…Although pharmaceutical and biological evaluations have been done on BSA-NPs for DL, investigations into the interactions between drugs and BSA at the atomic level are lacking. With the development of digital technology, computer modeling can assist in the rational design of DDSs with improved and optimized technologies 54. Complementary experimental and computational studies could enhance our understanding of the underlying interactions of BSA with drug molecules.…”

Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery

“…Viral delivery has been used to delivery genes to target cells with relatively high efficiency. Though less efficient, non-viral carriers, such as nanocarbon assemblies 9 , inorganic nanoparticles 10,11 , and liposomes 12,13 , generally have a lower potential for inducing side effects.…”